Thirty-one patients with small-cell lung cancer (SCLC) were treated with VP-16 and cisplatin
as first-line therapy. In the majority of cases an Adriamycin (Adria Laboratories, Columbus, …

… The authors thank Sandoz Barcelona for supplying the VP 16… 16 in disseminated lung
cancer, especially in the small cell … of the VP 16Cyclophosphamide combination on our Lung/2 …

… cell lung cancer were randomized to receive one of three treatment schedules of VP-16-213 …
The following treatment schedules were compared: Group A-VP-16-213 at a dose of 250 mg…

… We conclude that VP- 16-2 I3 is one of the most active agents against small cell lung cancer,
but it should not be cmployed as a single agent because it only induces a brief remission. …

… small cell lung cancer cell line by selection in etoposide (VP-16). … The rates of VP-16 efflux
are the same in the resistant and … Fewer VP-16-induced DNA-protein complexes are observed …

… patients with histologically documented lung cancer were treated with VP16 and … VP-16
plus cyclophosphamide is a well tolerated regimen with positive effect in advanced lung cancer…

… -lung-cancer (NSCLC) cells H1437 harboring p53 alleles (proline-267) can be inhibited by
low-dosage topoisomerase II inhibitor etoposide (VP-16… the sixth day of VP-16 treatment. The …

… of VP-16 and cisplatin is one of the most active regimens available for the treatment of small
cell lung cancer (SCLC… To investigate the problem of resistance to VP-16 and cisplatin in pa- …

… untreated patients with advanced non-small-cell lung cancer were treated in a randomized
trial comparing platinum (60 mg/m 2), doxorubicin (40 mg/m 2), and VP-16 (150 mg/m 2)(PAV…

… VP-16*(Etoposide),(Vepiside),(4’-demethylepipodophyllotaxing-D-ethylidene glucoside) in
the treatment of lung cancer. … treatment of the other types of lung cancer (NSCLC) is arguable. …